BLOG

How SunAct Offers Advanced Cancer Cellular Therapies Across India Empowering Patients with Cutting-Edge, Affordable Treatments

05 July 2025

Table of Contents

Introduction

Cancer remains one of the most pressing global health challenges, with India witnessing a growing number of new diagnoses each year. While conventional treatments such as chemotherapy and radiation therapy have been the mainstay for decades, advances in biomedical research have ushered in a new era: cellular therapies. These therapies promise more precise, personalised, and potentially curative options. 

This blog explores how SunAct – Advanced Cancer Therapies is transforming cancer care in India by offering cutting-edge cellular therapies. We outline the types of therapies available, their unique benefits, and how SunAct is making these innovations accessible and affordable across the country.

Targeted cancer cell therapy illustration highlighting SunAct’s advanced cancer cellular therapies in India

Understanding Cellular Therapies

What Are Cellular Therapies?

Cellular therapies utilize living cells, often from the patient, to treat diseases by enhancing the immune system’s ability to recognize and destroy cancer cells. These approaches offer targeted, durable responses and reduced toxicity compared to traditional therapies

Types of Cellular Therapies

  • CAR T-Cell Therapy: Patient’s T-cells are genetically modified to express chimeric antigen receptors
    (CARs) that target cancer cells.
  • TCR Therapy: T-cells are engineered to recognize cancer-specific antigens presented via MHC
    molecules.
  • TIL Therapy: Uses tumor-infiltrating lymphocytes harvested from the patient’s tumor, expanded in a lab, and reinfused to attack cancer.
  • Gamma Delta T-Cell Therapy: Exploits a distinct subset of T-cells with innate anti-tumor
    capabilities across various cancers.
  • Gene and CRISPR-Based Therapies: Employ gene editing tools to correct mutations or enhance
    immune responses.

The Need for Advanced Cancer Treatments in India

India faces a rising burden of cancer, with many patients presenting at advanced stages. While standard treatments such as chemotherapy, radiation, and surgery remain effective and form the backbone of cancer management, there remains a need for additional, innovative options, particularly for relapsed, refractory, or resistant disease. 

Cellular therapies offer a complementary approach that can extend survival, enhance disease control, and provide renewed hope even when standard treatments have been exhausted or have reached their therapeutic limit. These therapies represent a significant step forward in personalized and precision oncology.

SunAct: Pioneering Cancer Care

About SunAct

SunAct – Advanced Cancer Institute is a leading oncology center in India focused on next-generation treatments. Founded by distinguished oncologists Dr. Vijay Patil and Dr. Ashay Karpe, SunAct integrates clinical expertise with innovation to deliver transformative care.

Vision and Mission

SunAct is committed to democratizing access to cutting-edge therapies by making them affordable, evidence-based, and patient-centric. Their mission is to revolutionize the Indian oncology landscape through technology, research, and strategic partnerships.

SunAct’s Advanced Cellular Therapies

CAR T-Cell Therapy

SunAct offers both autologous (patient-derived) and allogeneic (donor-derived) CAR T-cell therapies for hematologic malignancies such as B-cell leukemias, lymphomas, and multiple myeloma. Research efforts are ongoing for their use in solid tumors.

TCR Therapy

TCR therapy is tailored to enhance T-cells’ recognition of tumor-associated antigens, enabling targeted elimination of solid tumors like melanoma, sarcoma, and lung cancer. 

Tumor-Infiltrating Lymphocyte (TIL) Therapy

SunAct employs TIL therapy by extracting immune cells directly from tumors, expanding them ex vivo, and reinfusing them for a focused anti-tumor response—especially for melanoma, cervical, and other solid tumors.

Gamma Delta T-Cell Therapy

SunAct is conducting Phase 2 clinical trials of Gamma Delta T-cell therapy for aggressive cancers such as brain, breast, and lung cancers. 

Gene and CRISPR Therapies

SunAct is exploring gene editing platforms such as CRISPR-Cas9 to correct oncogenic mutations and improve therapeutic precision in difficult-to-treat malignancies.

Comparative Overview of Cellular Therapies

Therapy TypeCell SourceMechanismCancer TypesPersonalizationClinical Stage
CAR T-Cell TherapyAutologous / AllogeneicCAR-modified T-cells targeting tumor antigensHematologic cancers (e.g., B-cell malignancies)Highly personalizedApproved, expanding into trials
TCR-T Cell TherapyAutologousTCR-enhanced T-cells recognizing MHC-bound tumor antigensMelanoma, lung, sarcomaHighly personalizedInvestigational, trial use
TIL TherapyAutologous (from tumor)Expansion of tumor-resident lymphocytesMelanoma, cervical, other solid tumorsHighly personalizedClinical and investigational use
NK Cell TherapyAutologous / AllogeneicInnate immune attack via stress ligand recognitionLymphoma, leukemia, some solid tumorsSemi-personalizedEmerging applications
Dendritic Cell TherapyAutologousAntigen-pulsed dendritic cells activating T-cell responsesGlioblastoma, prostate, melanomaPersonalizedApproved and investigational

SunAct’s Nationwide Presence

SunAct is expanding to ensure equitable access across India: 

  • Thane (Mumbai): Flagship center at Tieten Medicity Hospital.
  • Khar (Mumbai): Recently inaugurated Center of Excellence.
  • Nashik: Specializing in advanced cellular therapies and bone marrow transplantation.
  • Thodupuzha (Kerala): Partnership with Smita Memorial Hospital for advanced cellular therapies and bone marrow transplantation.

Affordability and Accessibility

SunAct’s mission includes reducing the cost barrier for Indian patients. Through optimized manufacturing and local partnerships: 

  • Cellular therapies at SunAct begin at ₹35 lakhs, a fraction of the cost in the US (₹2–3 crore). 
  • Support programs assist eligible patients with financial aid and insurance navigation. 

FAQs

SunAct’s flagship center is in Thane, Maharashtra. Address: Tieten Medicity (Old Vedant Hospital), Ghodbunder Road, Kasarvadavali, Thane West, Maharashtra 400615 however we are also present in Khar, Kerala (Thodupuzha), Nashik and Kerala. You can check the contact section of our website.

We offer: - Cellular Therapies: CAR-T, TCR, TIL, Stem Cell Therapy - Conventional Therapies: Chemotherapy, Radiotherapy, Surgery - Targeted and Immunotherapies Supportive services include nutrition, counseling, and rehabilitation

Each case undergoes multidisciplinary review, with plans customized based on cancer type, stage, genetic profile, and overall health. Teleconsults are available.

Patients receive personalized follow-up care, survivorship planning, and rehabilitation services.

Yes. Patients meeting eligibility may enroll in cutting-edge trials under SunAct’s research wing.

Conclusion

SunAct – Advanced Cancer Therapies stands at the forefront of next-generation cancer treatment in India. By combining cellular innovation, global collaborations, and a vision of equitable access, SunAct is reshaping the oncology landscape—offering renewed hope for patients and families across the country. 

Contact Information

📞 Phone: +91 86553 13412 

📞 Toll-Free: 1800 202 2232 

📧 Email: [email protected] 

🌐 Website: www.sunactcancer.com

Facebook
Twitter
LinkedIn
Email

Have Questions?

Fill in the details below.

Share your details below, and we’ll reach out to you without delay.

Disclaimer : We will be using this information for calling purposes only.

Share your details below, and we’ll reach out to you without delay.

Disclaimer : We will be using this information for calling purposes only.

Share your details below, and we’ll reach out to you without delay.

Disclaimer : We will be using this information for calling purposes only.

SunAct genitourinary cancer case study on GPC3-targeted CAR T therapy for refractory non-seminomatous germ cell tumor
SunAct genitourinary cancer case study on GPC3-targeted CAR T therapy for refractory non-seminomatous germ cell tumor
SunAct colon cancer case study highlighting TCR-based approach in metastatic colon cancer with lung lesions
SunAct colon cancer case study highlighting TCR-based approach in metastatic colon cancer with lung lesions
SunAct breast cancer case study showcasing HER2-positive treatment with CAR T-cell therapy
SunAct breast cancer case study showcasing HER2-positive treatment with CAR T-cell therapy
SunAct head and neck cancer case study using TCR-p53 therapy in inoperable squamous cell carcinoma
SunAct case study featuring gamma delta T-cell therapy for recurrent tongue carcinoma with extensive metastasis
SunAct case study featuring gamma delta T-cell therapy for recurrent tongue carcinoma with extensive metastasis
SunAct head and neck cancer case study on salivary ductal carcinoma managed with advanced therapies
SunAct head and neck cancer case study on salivary ductal carcinoma managed with advanced therapies
SunAct case study on GD2-targeted CAR T therapy for diffuse midline glioma in a 22-year-old male
SunAct case study on GD2-targeted CAR T therapy for diffuse midline glioma in a 22-year-old male
SunAct CNS case study on GBM treatment using multiple gene mutation targeting in a 36-year-old male
SunAct CNS case study on GBM treatment using multiple gene mutation targeting in a 36-year-old male